176 related articles for article (PubMed ID: 28544814)
1. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
2. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
3. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.
Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB
Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657
[TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
5. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
6. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
7. DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation.
Leung AWY; Chen KTJ; Ryan GM; Anantha M; Wretham N; Nosrati Z; Heroux D; Wang L; Chow N; Dai Z; Bally MB
J Control Release; 2022 May; 345():75-90. PubMed ID: 35259461
[TBL] [Abstract][Full Text] [Related]
8. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
9. Copper-topotecan complexation mediates drug accumulation into liposomes.
Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
[TBL] [Abstract][Full Text] [Related]
10. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
Jain A; Jain SK
Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
[TBL] [Abstract][Full Text] [Related]
11. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator?
Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N
Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563
[TBL] [Abstract][Full Text] [Related]
12. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone.
Lim HJ; Masin D; Madden TD; Bally MB
J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545
[TBL] [Abstract][Full Text] [Related]
13. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
14. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.
Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y
Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809
[TBL] [Abstract][Full Text] [Related]
15. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design.
Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S
Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751
[TBL] [Abstract][Full Text] [Related]
16. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
17. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
18. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
Sottile F; Gnemmi I; Cantilena S; D'Acunto WC; Sala A
Oncotarget; 2012 May; 3(5):535-45. PubMed ID: 22619121
[TBL] [Abstract][Full Text] [Related]
19. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
